Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $1.29 billion. The enterprise value is $1.08 billion.
Important Dates
The next estimated earnings date is Monday, November 10, 2025, after market close.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TRVI has 121.78 million shares outstanding. The number of shares has increased by 14.02% in one year.
| Current Share Class | 121.78M |
| Shares Outstanding | 121.78M |
| Shares Change (YoY) | +14.02% |
| Shares Change (QoQ) | +10.83% |
| Owned by Insiders (%) | 0.81% |
| Owned by Institutions (%) | 68.42% |
| Float | 90.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.46 |
| P/TBV Ratio | 6.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.42, with a Debt / Equity ratio of 0.00.
| Current Ratio | 22.42 |
| Quick Ratio | 22.15 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25,760.50 |
Financial Efficiency
Return on equity (ROE) is -35.74% and return on invested capital (ROIC) is -24.14%.
| Return on Equity (ROE) | -35.74% |
| Return on Assets (ROA) | -22.83% |
| Return on Invested Capital (ROIC) | -24.14% |
| Return on Capital Employed (ROCE) | -25.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.82M |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -46,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +237.74% in the last 52 weeks. The beta is 0.74, so TRVI's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +237.74% |
| 50-Day Moving Average | 8.96 |
| 200-Day Moving Average | 6.69 |
| Relative Strength Index (RSI) | 64.96 |
| Average Volume (20 Days) | 1,551,447 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -51.52M |
| Pretax Income | -47.34M |
| Net Income | -47.30M |
| EBITDA | -51.37M |
| EBIT | -51.52M |
| Earnings Per Share (EPS) | -$0.42 |
Full Income Statement Balance Sheet
The company has $203.89 million in cash and $891,000 in debt, giving a net cash position of $202.99 million or $1.67 per share.
| Cash & Cash Equivalents | 203.89M |
| Total Debt | 891,000 |
| Net Cash | 202.99M |
| Net Cash Per Share | $1.67 |
| Equity (Book Value) | 198.49M |
| Book Value Per Share | 1.63 |
| Working Capital | 197.99M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$42.68 million and capital expenditures -$7,000, giving a free cash flow of -$42.69 million.
| Operating Cash Flow | -42.68M |
| Capital Expenditures | -7,000 |
| Free Cash Flow | -42.69M |
| FCF Per Share | -$0.35 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRVI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.02% |
| Shareholder Yield | -14.02% |
| Earnings Yield | -3.69% |
| FCF Yield | -3.33% |
Analyst Forecast
The average price target for TRVI is $20.72, which is 96.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.72 |
| Price Target Difference | 96.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -13.08% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |